Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

Approximately 40% of sales were due to doses administered to patients and the remainder were due to inventory building. Merck’s Animal ... of its key products led by Keytruda.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Switzerland’s total lack of patent laws led ... by Merck (MSD). New challenges in an age of innovation The 2010s have seen the development of innovative new classes of medicines, building ...

A pharmaceutical heir is traveling the globe selling multimillion-dollar apartments on his yet-to-be-built boat.

but it led to higher rates of adverse events, including ones that resulted in death, Merck said. The study tested the pairing against stereotactic body radiotherapy alone. After reviewing the data ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

The Winrevair combination led to a statistically significant and clinically meaningful ... growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s… legacy in ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...